"For preventing the onset of CIPN, the committee recommended further
clinical testing of intravenous calcium and magnesium, which reduced
CIPN symptoms by approximately half compared with a placebo in one trial
involving patients receiving oxaliplatin;
a peptide called glutathione,
which is thought to bind to heavy metals and has shown promise in small
trials in patients who are treated with platinum chemotherapies; acetyl-L-carnitine,
a substance that was effective in animal models and in patients with
diabetes and HIV; and the antioxidant alpha-lipoic acid.
Pharmacogenomic studies will also, it is hoped, help guide the
identification of patients who are more or less likely to develop CIPN.
One such study is being planned at the Mayo Clinic to determine how a
variation in genes that control taxane and carboplatin metabolism may
affect a person’s risk of getting CIPN."
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.